Study of EVO756 in Adults With Migraine

Brief summary (registry, in English)

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 330
• From 29 Jul 2026 to the primary completion date, 31 Oct 2027
• 35 sites in 3 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (35)

Sites in registry order. Pick your city on the disease page to sort them by distance.